XORTX Initiates Precision Medicine Program
XORTX Therapeutics Inc. (XRTX)
Company Research
Source: GlobeNewswire
CALGARY, Alberta, Oct. 09, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company has initiated a precision medicine program. On August 29, 2024, XORTX announced that independent peer-reviewed research reported that genetic factors are linked to the over-expression of xanthine oxidase (“XO”) and play a role in several diseases, including kidney disease. These ground-breaking findings provide an opportunity to expand the Company’s programs and approach by combining genetic diagnostics focused on treating kidney and diseases such as sepsis by inhibiting XO with xanthine oxidase inhibition targeting individuals most in need. Recent pioneering discoveries provide XORTX with the opportunity to develop diagnostics that identify specific genetic factors. These
Show less
Read more
Impact Snapshot
Event Time:
XRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XRTX alerts
High impacting XORTX Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
XRTX
News
- XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024GlobeNewswire
- XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswire
- XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement [Financial Post (Toronto, Ontario, Canada)]Financial Post
- XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswire
XRTX
Sec Filings
- 11/15/24 - Form F-1
- 11/15/24 - Form 6-K
- 10/31/24 - Form D
- XRTX's page on the SEC website